Measuring Fatigue Induced Changes In 3d Trunk Kinematics, Measured By Inertial Magnetic Measurement Units.: 2286 Board #4 June 2, 3: 15 PM - 5: 15 PM.

J. Reenalda,Erik Maartens

DOI: https://doi.org/10.1249/01.mss.0000486907.47758.cb

2016-05-01

Medicine & Science in Sports & Exercise

Abstract:

What problem does this paper attempt to address?

["Medical decision making in the tension field between medical possibilities, cost pressure and humanity."]

K Vilmar

Abstract:The progress in medicine has contributed to the fact that for 50 years life expectancy in Germany has increased by three to four years per decade. The number of older people has considerably increased and at the same time there has been a decline in the birthrate with the effect that the portion of the people over 60 years, now a quarter of the population, will rise to a third of the population in 2040. The dual relationship between patient and physician has changed due to the extension of the statutory health insurance to more than 90% of the population. Today collective contracts made with the statutory health insurance determine the preconditions for entitlement, but often with uncertain legal concepts. The expenditure which occurred due to the demographic and epidemiologic changes caused the limitations of the contribution rates by the legislator. The health insurance funds have implemented further regementations by means of health care duties and action for recourse in case of exceeding the budget. Thus the politically intended limitation of the resources can bring the physician in a decision emergency condition or even in an ethical dilemma. He has to observe legal rules, especially in the field of the criminal law and the liability law. Thus the financial, organizational and structural deficits in the health care system that are resulting from the social legislation are shifted by means of the liability law to the individual physician or to other service providers. Even treatment guidelines cannot protect them from this because the "standard patient" does not exist. What we really need are appropriate reforms including adjustments of the insurance structures which offer the insured alternatives: Expansion of the financial elements of the statutory health insurance Adjustments of the health care structures with integration between the outpatient and inpatient sector Restriction of the legislator to the definition of framework provisions and service limits Orientation of the health care necessities to the health care needs of the patients Economy must not dominate over humanity Adjustment of the social legislation and the liability law Settlement of the details by the joint self-administration of physicians and health insurance funds.
Physicians, Cost Control, and Ethics

D P Sulmasy,Daniel P. Sulmasy

DOI: https://doi.org/10.7326/0003-4819-116-11-920

IF: 39.2

1992-06-01

Annals of Internal Medicine

Abstract:Rising health care expenditures have led to numerous cost-control proposals. An examination of the ethical questions surrounding the role that physicians play in the control of health care costs suggests that unilateral rationing decisions by individual physicians at the bedside are morally unacceptable. Such decisions are arbitrary, ineffective in redistributing health care resources, and formally unjust. Restrictive gatekeeping (the creation of financial incentives for physicians to limit care given to individual patients) also seems unacceptable because of its morally significant effects. First, it disguises the role of those actually responsible for cost-control decisions; second, it routinely creates a "moral stress test" by forcing physicians to act in ways that are contrary to their own interests in order to serve the needs of patients; third, it undermines the trust between doctor and patient; and fourth, it rations by class of persons rather than class of technology. In contrast, a morally sound system would attempt to control costs by honestly informing patients and assigning responsibility justly, would encourage physicians to act in the interests of patients, would foster trust, and would recognize the great importance of equal treatment for all patients. Such a system would depend on input from an informed public and would apply equally to all members of society.

medicine, general & internal
[Limitations to the physician's discretionary and therapeutic freedom and to the provision of health care for the general population by a shortage of financial and human resources--the rules of Section 2 Para. 1 and 4 of the Medical Professional Code of conduct and how much they are really worth]

Jörg-Dietrich Hoppe

DOI: https://doi.org/10.1016/j.zgesun.2007.08.035

Abstract:Up to the early 1990's the health care system was essentially characterised through:--the insured' right of choice of therapist,--therapeutic freedom of patients and physicians, and--the freedom of establishment for medical doctors.--In accordance with the Hospital Funding Act the hospital system was--in compliance with federal constitutional law using capacity requirements--based on the "fire-fighting" principle, i.e. that if required, every patient should have access to a suitable hospital bed within about 15 minutes.--The responsibility for ensuring the provision of general and specialist health care services had been conferred by the government to the National Association of Statutory Health Insurance Physicians (1955) in the legal form of a public corporation. In the face of a foreseeable rise in expenses as a result of advances in medicine and a higher demand for health care services because of the demographic development (long-life society) the Advisory Council for Concerted Action in Health Care concludes in its Annual Report that maintaining this level of health care for all people is not financially viable any longer. This is why the state--on the basis of the Health Care Reform Act of 2002 and the Statutory Health Insurance System Modernisation Act of 2004--retreated from the provision of services in the ambulatory and inpatient setting by privatising these sectors and by proclaiming competition (introduction of diagnosis-related groups). Presently, the once liberal performance tradition is more and more turning into a centrally planned system in the spirit of "From Therapeutic Freedom to Therapeutic Programmes". The guidelines that on the basis of the methods of evidence-based medicine were developed by the international community of physicians for the treatment of patients with defined diagnoses and intended to be decision aids for individual treatment decisions are now used to implement disease management programmes for the provision of health care to people with certain chronic diseases. Another steering instrument of the above mentioned Modernisation Act is the definition of a list stating all the benefits available under the statutory health insurance system. The assessment of the health gain of new medical drugs and other medical procedures has been assigned to the Institute for Quality and Efficiency in Health Care (IQWiG) specifically founded to that purpose. With regard to the assessment of diagnostic and therapeutic procedures the Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA) in the summer of 2005 gave itself a Code of Procedures that defines uniform cross-sector criteria for the appraisal of diagnosis and treatment. In Germany the principle of evidence-based health care has by law--and this is unique as compared to other countries--fully penetrated everyday health care where the decisions of the Joint Federal Committee in the form of directives have mandatory effect for health care providers and hence for the insured, too. This is why the German Medical Association and the National Association of Statutory Health Insurance Physicians have embarked on the implementation of the "National Programme for Disease Management Guidelines" and the "Health Services Research" Project as a means of continuously evaluating health care provision which are intended to guide the future political control of the system of statutory health insurance in terms of target-performance comparisons and for the purpose of identifying health care deficits.
Effective healthcare cost-containment policies: A systematic review

Niek Stadhouders,Florien Kruse,Marit Tanke,Xander Koolman,Patrick Jeurissen

DOI: https://doi.org/10.1016/j.healthpol.2018.10.015

IF: 3.255

2019-01-01

Health Policy

Abstract:Unsustainable growth in healthcare expenditure demands effective cost-containment policies. We review policy effectiveness using total payer expenditure as primary outcome measure. We included all OECD member states from 1970 onward. After a rigorous quality appraisal, we included 43 original studies and 18 systematic reviews that cover 341 studies. Policies most often evaluated were payment reforms (10 studies), managed care (8 studies) and cost sharing (6 studies). Despite the importance of this topic, for many widely-used policies very limited evidence is available on their effectiveness in containing healthcare costs. We found no evidence for 21 of 41 major groups of cost-containment policies. Furthermore, many evaluations displayed a high risk of bias. Therefore, policies should be more routinely and rigorously evaluated after implementation. The available high-quality evidence suggests that the cost curve may best be bent using a combination of cost sharing, managed care competition, reference pricing, generic substitution and tort reform.

health care sciences & services,health policy & services
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.

Z. Szulc,A. Bai,J. Bielawski,Nalini Mayroo,Doreen E Miller,H. Gracz,Y. Hannun,A. Bielawska

DOI: https://doi.org/10.1016/j.bmc.2010.08.050

IF: 3.461

2010-11-01

Bioorganic & Medicinal Chemistry

Abstract:
Comparison of the Burkard and Allergenco MK-3 volumetric collectors.

J. Portnoy,J. Landuyt,F. Pacheco,S. Flappan,S. Simon,C. Barnes

DOI: https://doi.org/10.1016/S1081-1206(10)62735-4

Abstract:
Ethics in Practice: Managed Care and the Changing Health Care Environment

Gail J. Povar,Helen Blumen,John Daniel,Suzanne Daub,Lois Evans,Richard P. Holm,Natalie Levkovich,Alice O. McCarter,James Sabin,Lois Snyder,Daniel Sulmasy,Peter Vaughan,Laurence D. Wellikson,Amy Campbell,,

DOI: https://doi.org/10.7326/0003-4819-141-2-200407200-00012

IF: 39.2

2004-07-20

Annals of Internal Medicine

Abstract:Cost pressures and changes in the health care environment pose ethical challenges and hard choices for patients, physicians, policymakers, and society. In 2000 and 2001, the American College of Physicians, with the Harvard Pilgrim Health Care Ethics Program, convened a working group of stakeholders--patients, physicians, and managed care representatives, along with medical ethicists--to develop a statement of ethics for managed care. The group explored the impact of a changing health care environment on patient-physician relationships and how to best apply the principles of professionalism in this environment. The statement that emerged offers guidance on preserving the patient-clinician relationship, patient rights and responsibilities, confidentiality and privacy, resource allocation and stewardship, the obligation of health plans to foster an ethical environment for the delivery of care, and the clinician's responsibility to individual patients, the community, and the public health, among other issues.

medicine, general & internal
The impact of market-based 'reform' on cultural values in health care

L L Curtin

Abstract:The many issues managed care poses for providers and health networks are crystallized in the moral problems occasioned by its shifting of the financial risks of care from insurer to provider. The issues occasioned by market-based reform include: the problems presented by clashes between public expectations and payer restrictions; the corporatization of health service delivery and the cultural shift from humanitarian endeavor to business enterprise the depersonalization of treatment as time and money constraints stretch resources, and the culture rewards efficient "business-like" behavior the underfunding of care for the poor and uninsured, even as these populations grow the restructuring of care and reengineering of healthcare roles as the emphasis shifts from quality of care to conservation of resources rapid mergers of both health plans and institutional providers with all the inherent turmoil as rules change, services are eliminated, and support services are minimized to save money the unhealthy competition inherent in market-based reform that posits profit taking and market share as the measures of successful performance the undermining of the professional ethic of advocacy the use of incentives that pander to greed and self-interest. The costs of sophisticated technologies and the ongoing care of increasingly fragile patients have pulled many other elements into what previously were considered "privileged" professional interactions. The fact that very few citizens indeed could pay out-of-pocket for the treatment and ongoing care they might need led to social involvement (few people remember that both widespread health insurance and public programs are relatively recent phenomena--only about 30 years old). However, whether in tax dollars or insurance premiums, other people's money is being spent on the patient's care. Clearly, those "other people" never intended to give either the patient or the professional open-ended access to their collective pocketbooks. Just what form their involvement ought to take is being tested as "managed care" attempts to control the costs. What limits are acceptable to providers?: lower profit margins? quality controls? acceptable risk levels? To patients?: restricted choice? restricted mobility? restricted access to high tech? And to the general public?: decreased access to high tech? higher taxes? underserved populations? Abandonment of the sick or poor? Which "techniques" are acceptable, and which are not?: risk-sharing with providers? financial incentives for decision makers? rationing access? imposing behavioral parameters? The issues posed by market-based managed care cannot be adequately addressed merely in terms of social resources, nor will answers be found in subordinating human rights to practical materialism. Negotiating ethical guidelines for the "safe" handling of such problems to the good of individuals and of society requires a revitalization of the "old" values: the old commitment to master craftsmanship and altruism, the old emphasis on patient advocacy and human rights. However, these old values must be applied with the "new" knowledge of lifestyle choices (and thus personal responsibility), likely outcomes (and thus reasonable options), and the limits of success (and thus fair redeployment of health resources).
The role of human capital and stress for cost awareness in the healthcare system: a survey among German hospital physicians

Christoph Lüdemann,Maike Gerken,Marcel Hülsbeck

DOI: https://doi.org/10.1186/s12913-024-10748-z

2024-03-09

BMC Health Services Research

Abstract:Germany has the highest per capita health care spending among EU member states, but its hospitals face pressure to generate profits independently due to the government's withdrawal of investment cost coverage. The diagnosis related groups (DRG) payment system was implemented to address the cost issue, challenging hospital physicians to provide services within predefined prices and an economic target corridor to reduce costs. This study examines the extent of cost awareness among medical personnel in German hospitals and its influencing factors.

health care sciences & services
Future European health care: cost containment, health care reform and scientific progress in drug research

G Emilien

DOI: https://doi.org/10.1002/(SICI)1099-1751(199704)12:2<81::AID-HPM460>3.0.CO;2-3

Abstract:The cost of the development of a new pharmaceutical product from its conception and synthesis through to the regulatory approval process has more than quadrupled in the last 20 years. Both clinical and total development times have increased substantially. To amortize the costs incurred, the pharmaceutical industry has taken an international dimension. The incentives for pharmaceutical firms to discover and develop new drugs depend on the length of the development and regulatory review process plus the potential market size. Recent regulatory, economic and political changes may have significant implications for the future of new drug developments in Europe. The European Union industrial policy felt that there is a need for convergence in the area of pricing. It is recommended that the policy should aim to contain growth in pharmaceutical expenses by means specific to reimbursement rather than direct price controls. By encouraging doctors to prescribe and customers to use generics, competition is enhanced to bring down drug prices. More emphasis is being laid by government in educating customers to cost-awareness and cost-benefit ratios with regard to pharmaceuticals. Concerning clinical trials, European harmonization has been achieved by significant developments: the rights and integrity of the trial subjects are protected; the credibility of the data is established; and the ethical, scientific and technical quality of the trials has improved. Future European health care forecasts a whole change in the pharmaceutical business. Important issues in cost and outcome measurement should be carefully planned and considered in drug development. Due to important mergers and acquisitions, the pharmaceutical sector will consist mainly of important multinational corporations. In this way, valuable new products may be brought to the market.
Pricing, profits and pharmacoeconomics--for whose benefit?

J R Adams,S Ali,C L Bennett

DOI: https://doi.org/10.1517/14656566.2.3.377

Abstract:In today's troubled healthcare climate, it is not uncommon to run across headlines like: 'Health insurance premiums increasing by 10 percent to 30 percent across the country.' This particular New York Times article went on to explain that this premium price hike, the third consecutive double digit increase in 3 years, is driven largely by escalating pharmaceutical costs. The pharmaceutical industry has largely been vilified in the media and in the recent presidential debates, for fueling healthcare inflation and setting what many perceive to be 'unfair' prices in light of the profit margins on their life-saving products. A report released by the Congressional Research Service found that after tax, profits for the pharmaceutical industry averaged 17% of sales, compared with 5% for all other industries. The White House has added its voice to the popular discontent with notices such as this one reported in the New York Times: 'There is a rising tide politically in this country of strong antagonism against the pharmaceutical industry on the dimension of prices. (Without expanded access to insurance) price controls are an inevitable outcome.' Although the prospect of price control remains dubious in America's entrenched laissez-faire economy, David Kessler, former head of the FDA and the Dean of the Yale School of Medicine, described the situation as a 'powder keg,' stating 'the current system is simply not sustainable'. Although there does not appear to be an immediate solution to this escalating crisis, this editorial will examine pharmaceutical pricing, industry profits and the role of pharmacoeconomic analyses amidst the chaos.
Doctors as Resource Stewards? Translating High-Value, Cost-Conscious Care to the Consulting Room

Marjolein Moleman,Teun Zuiderent-Jerak,Marianne Lageweg,Gianni L. van den Braak,Tjerk Jan Schuitmaker-Warnaar

DOI: https://doi.org/10.1007/s10728-022-00446-4

2022-05-14

Health Care Analysis

Abstract:After many policy attempts to tackle the persistent rise in the costs of health care, physicians are increasingly seen as potentially effective resource stewards. Frameworks including the quadruple aim, value-based health care and choosing wisely underline the importance of positive engagement of the health care workforce in reinventing the system–paving the way to real affordability by defining the right care. Current programmes focus on educating future doctors to provide 'high-value, cost-conscious care' (HVCCC), which proponents believe is the future of sustainable medical practice. Such programmes, which aim to extend population-level allocation concerns to interactions between an individual doctor and patient, have generated lively debates about the ethics of expanding doctors' professional accountability. To empirically ground this discussion, we conducted a qualitative interview study to examine what happens when resource stewardship responsibilities are extended to the consulting room. Attempts to deliver HVCCC were found to involve inevitable trade-offs between benefits to the individual patient and (social) costs, medical uncertainty and efficiency, and between resource stewardship and trust. Physicians reconcile this by justifying good-value care in terms of what is in the best interest of individual patients–redefining the currency of value from monetary costs to a patient's quality of life, and cost-conscious care as reflective medical practice. Micro-level resource stewardship thus becomes a matter of working reflexively and reducing wasteful forms of care, rather than of making difficult choices about resource allocation.

social sciences, biomedical,health policy & services,ethics
Covering digital health applications in the public insurance system: how to foster innovation in patient care while mitigating financial risks—evidence from Germany

Nicole Groene,Luca Schneck

DOI: https://doi.org/10.3389/fdgth.2023.1217479

2023-10-11

Frontiers in Digital Health

Abstract:Context Digital health applications that support patients in managing their condition can have a positive impact on patients' health and improve the overall care process. In late 2019, as the first country worldwide, Germany included digital health applications in the benefit basket of the statutory health insurance (SHI) system to enable fast, broad-scale patient access and encourage innovation in the digital health industry. While the policy is widely recognized as a pioneering step toward improving patient care through digital technologies, there are concerns regarding the mechanics of the policy and the resulting financial risks for the SHI system. Goals The primary objective of this article is to provide a comprehensive and balanced overview of the German policy by evaluating its success in achieving its goals and by reviewing challenges that have emerged. The secondary objective is to delineate prospective policy options and areas warranting future research. Approach The article analyzes publicly available data of the Federal Institute for Drugs and Medical Devices collected between February 1st and July 17th, 2023, and complements it with empirical findings published by academic institutions and sickness funds. It discusses policy options and related areas of future research to overcome the identified challenges without jeopardizing the purpose of the legislation to encourage innovation in the digital health industry to improve patient care. Conclusion In line with the goals of the reimbursement policy, the inclusion of digital health applications in the SHI benefit basked has entailed new digital treatment options for patients across multiple disease areas. However, from a health policy perspective, the policy has several shortcomings, including low prescription rates, the temporary reimbursement of digital health applications that lack proven benefit, and a pricing framework that does not take into account the efficacy and efficiency of a treatment and may lead to a suboptimal allocation of public resources. Rather than the public system covering digital health applications without proven benefit, the authors suggest giving SHI organizations more budget authority to directly incentivize research and development activities and to introduce value-based pricing. More research is needed to determine the details of these mechanisms.
German Health Care System:Recent Situations,Problems and Reform

DING Chun

2007-01-01

Abstract:German Health Care System, which is mainly founded on the Compulsory Health Care System imported by Bismarck dated to 1883, is a successful model most widely imitated throughout the world. However, along with the slowing down of German economic growth, the deterioration of the aging of population and the impacts of globalization, the systematic problems of financing, social solidarity and efficiency of health care provision have gradually emerged. The reform of the health care system seems inevitable and becomes the focus of the economic and social reforms implemented by the Merkel government. But there remain broad controversies as to the concrete steps to take. Based on the introduction of the status quo and the basic structure of German Health Care System, the paper analyzes the background of the health care reform carried out by the Merkel government, the different reform protocols proposed by different parties and the different notions underlying each protocol. This paper also comments on the main contents of the final act titled "Health Care Reform 2007", and points out the validity of the general aim of this reform which uses competition enhancement as the main instrument, covers unprecedented broad fields and which is oriented to multiple objectives. However, as a programme resulted from compromises by different parties, it is difficult to foresee its final result, which may not be positive.
Schwannoma of the parapharyngeal space.

F. Carinci,F. Carls,D. Grasso,S. Pelucchi,A. Pastore

DOI: https://doi.org/10.1097/00001665-200011040-00016

2000-07-01

Abstract:A schwannoma (or neurilemmoma) of the parapharyngeal space is a rare tumor in the head and neck region arising from the sheath of cranial nerves and/or the sympathetic chain. In the early stages of growth, there is usually a lack of symptoms because of the anatomical localization and slow growth of the tumor. The large dimension of the mass at presentation makes it difficult to perform a functional surgery, and in many cases the operation worsens the nerve status. The choice of surgical approach is of paramount importance in both preserving nerve function and achieving vascular control. The authors report a case and discuss the English literature.
Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility

Maria Hee Jung Park Frausing,Jens Cosedis Nielsen,Caroline Louise Westergaard,Christian Gerdes,Jakob Kjellberg,Giuseppe Boriani,Mads Brix Kronborg

DOI: https://doi.org/10.1093/europace/euae031

2024-02-01

Abstract:Cardiac electrophysiology is an evolving field that relies heavily on costly device- and catheter-based technologies. An increasing number of patients with heart rhythm disorders are becoming eligible for cardiac interventions, not least due to the rising prevalence of atrial fibrillation and increased longevity in the population. Meanwhile, the expansive costs of healthcare face finite societal resources, and a cost-conscious approach to new technologies is critical. Cost-effectiveness analyses support rational decision-making in healthcare by evaluating the ratio of healthcare costs to health benefits for competing therapies. They may, however, be subject to significant uncertainty and bias. This paper aims to introduce the basic concepts, framework, and limitations of cost-effectiveness analyses to clinicians including recent examples from clinical electrophysiology and device therapy.
Future Directions for Cost-effectiveness Analyses in Health and Medicine

Peter J Neumann,David D Kim,Thomas A Trikalinos,Mark J Sculpher,Joshua A Salomon,Lisa A Prosser,Douglas K Owens,David O Meltzer,Karen M Kuntz,Murray Krahn,David Feeny,Anirban Basu,Louise B Russell,Joanna E Siegel,Theodore G Ganiats,Gillian D Sanders

DOI: https://doi.org/10.1177/0272989X18798833

Abstract:Objectives: In 2016, the Second Panel on Cost-effectiveness in Health and Medicine updated the seminal work of the original panel from 2 decades earlier. The Second Panel had an opportunity to reflect on the evolution of cost-effectiveness analysis (CEA) and to provide guidance for the next generation of practitioners and consumers. In this article, we present key topics for future research and policy. Methods: During the course of its deliberations, the Second Panel discussed numerous topics for advancing methods and for improving the use of CEA in decision making. We identify and consider 7 areas for which the panel believes that future research would be particularly fruitful. In each of these areas, we highlight outstanding research needs. The list is not intended as an exhaustive inventory but rather a set of key items that surfaced repeatedly in the panel's discussions. In the online Appendix , we also list and expound briefly on 8 other important topics. Results: We highlight 7 key areas: CEA and perspectives (determining, valuing, and summarizing elements for the analysis), modeling (comparative modeling and model transparency), health outcomes (valuing temporary health and path states, as well as health effects on caregivers), costing (a cost catalogue, valuing household production, and productivity effects), evidence synthesis (developing theory on learning across studies and combining data from clinical trials and observational studies), estimating and using cost-effectiveness thresholds (empirically representing 2 broad concepts: opportunity costs and public willingness to pay), and reporting and communicating CEAs (written protocols and a quality scoring system). Conclusions: Cost-effectiveness analysis remains a flourishing and evolving field with many opportunities for research. More work is needed on many fronts to understand how best to incorporate CEA into policy and practice.
[From policlinic services to medical service centres--the Swiss perspective]

Dieter Conen

DOI: https://doi.org/10.1016/j.zefq.2009.09.014

Abstract:Industrialized countries are confronting the challenge of providing their population with accessible, high-quality, safe and efficient healthcare. They face the growing challenge of caring for an increasing number of patients suffering from chronic and complex diseases. Chronically ill patients see multiple clinicians at different healthcare sites, which increases the risks of errors and poor coordination. These experiences together with rising healthcare costs force the different healthcare systems in the industrialized countries to introduce and test new ways to offer healthcare while taking into account the entire chain of care. Disease management programmes together with institutions and structures like medical homes which are accessible and help to coordinate care make a difference for those patients. The German way to a better coordination of and a better access to healthcare is a step in the right direction, but there is a lack of data demonstrating the increase in effectiveness and efficiency. The opportunity has been missed to conduct pilot studies in order to identify measurable, reliable, and valid outcome indicators and thus create greater transparency. The question is not "whether" but "how" new ways of offering care can be introduced to increase the performance of the whole system, to decrease coordination problems, and to stabilise healthcare spending.
High and Rising Health Care Costs. Part 4: Can Costs Be Controlled While Preserving Quality?

Thomas Bodenheimer,Alicia Fernandez

DOI: https://doi.org/10.7326/0003-4819-143-1-200507050-00007

IF: 39.2

2005-07-05

Annals of Internal Medicine

Abstract:Several interrelated strategies involving physician leadership and participation have been proposed to contain health care costs while preserving or improving quality. These include programs targeting the 10% of the population that incurs 70% of health care expenditures, disease management programs to prevent costly complications of chronic conditions, efforts to reduce medical errors, the strengthening of primary care practice, decision support tools to avoid inappropriate services, and improved diffusion of technology assessment. An example of a cost-reducing, quality-enhancing program is post-hospital nurse monitoring and intervention for patients at high risk for repeated hospitalization for congestive heart failure. Disease management programs that target groups with a chronic condition rather than focusing efforts on high-utilizing individuals may be effective in improving quality but may not reduce costs. Error reduction has great potential to improve quality while reducing costs, although the probable cost reduction is a small portion of national health care expenditures. Access to primary care has been shown to correlate with reduced hospital use while preserving quality. Inappropriate care and overuse of new technologies can be reduced through shared decision-making between well-informed physicians and patients. Physicians have a central role to play in fostering these quality-enhancing strategies that can help to slow the growth of health care expenditures.

medicine, general & internal
In planta regulation of the Arabidopsis Ca(2+)/H(+) antiporter CAX1.

H. Mei,Jian Zhao,J. Pittman,J. Lachmansingh,Sunghun Park,K. Hirschi

DOI: https://doi.org/10.1093/JXB/ERM190

IF: 6.9

2007-09-01

Journal of Experimental Botany

Abstract:Vacuolar localized Ca(2+)/H(+) exchangers such as Arabidopsis thaliana cation exchanger 1 (CAX1) play important roles in Ca(2+) homeostasis. When expressed in yeast, CAX1 is regulated via an N-terminal autoinhibitory domain. In yeast expression assays, a 36 amino acid N-terminal truncation of CAX1, termed sCAX1, and variants with specific mutations in this N-terminus, show CAX1-mediated Ca(2+)/H(+) antiport activity. Furthermore, transgenic plants expressing sCAX1 display increased Ca(2+) accumulation and heightened activity of vacuolar Ca(2+)/H(+) antiport. Here the properties of N-terminal CAX1 variants in plants and yeast expression systems are compared and contrasted to determine if autoinhibition of CAX1 is occurring in planta. Initially, using ionome analysis, it has been demonstrated that only yeast cells expressing activated CAX1 transporters have altered total calcium content and fluctuations in zinc and nickel. Tobacco plants expressing activated CAX1 variants displayed hypersensitivity to ion imbalances, increased calcium accumulation, heightened concentrations of other mineral nutrients such as potassium, magnesium and manganese, and increased activity of tonoplast-enriched Ca(2+)/H(+) transport. Despite high in planta gene expression, CAX1 and N-terminal variants of CAX1 which were not active in yeast, displayed none of the aforementioned phenotypes. Although several plant transporters appear to contain N-terminal autoinhibitory domains, this work is the first to document clearly N-terminal-dependent regulation of a Ca(2+) transporter in transgenic plants. Engineering the autoinhibitory domain thus provides a strategy to enhance transport function to affect agronomic traits.

Measuring Fatigue Induced Changes In 3d Trunk Kinematics, Measured By Inertial Magnetic Measurement Units.: 2286 Board #4 June 2, 3: 15 PM - 5: 15 PM.

["Medical decision making in the tension field between medical possibilities, cost pressure and humanity."]

Physicians, Cost Control, and Ethics

[Limitations to the physician's discretionary and therapeutic freedom and to the provision of health care for the general population by a shortage of financial and human resources--the rules of Section 2 Para. 1 and 4 of the Medical Professional Code of conduct and how much they are really worth]

Effective healthcare cost-containment policies: A systematic review

Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.

Comparison of the Burkard and Allergenco MK-3 volumetric collectors.

Ethics in Practice: Managed Care and the Changing Health Care Environment

The impact of market-based 'reform' on cultural values in health care

The role of human capital and stress for cost awareness in the healthcare system: a survey among German hospital physicians

Future European health care: cost containment, health care reform and scientific progress in drug research

Pricing, profits and pharmacoeconomics--for whose benefit?

Doctors as Resource Stewards? Translating High-Value, Cost-Conscious Care to the Consulting Room

Covering digital health applications in the public insurance system: how to foster innovation in patient care while mitigating financial risks—evidence from Germany

German Health Care System:Recent Situations,Problems and Reform

Schwannoma of the parapharyngeal space.

Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility

Future Directions for Cost-effectiveness Analyses in Health and Medicine

[From policlinic services to medical service centres--the Swiss perspective]

High and Rising Health Care Costs. Part 4: Can Costs Be Controlled While Preserving Quality?

In planta regulation of the Arabidopsis Ca(2+)/H(+) antiporter CAX1.